Sunday, November 24

Zydus’ biopharma arm acquires global proprietary rights for Progeria treatment

Sentynl, under Zydus Lifesciences, acquired global rights for Zokinvy, the first FDA-approved Progeria treatment. An acquisition milestone in expanding the rare disease medicines portfolio, focusing on supporting patients.
  • News Source Indiatimes (Click to view full news): CLICK HERE
  • Share:

0 Comments:

Leave a Reply

Your email address will not be published. Required fields are marked *

Format: 987-654-3210